Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chlamydophila pneumonia vaccine - Antex Biologics

Drug Profile

Chlamydophila pneumonia vaccine - Antex Biologics

Alternative Names: TWARVAX

Latest Information Update: 25 Nov 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antex Biologics
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Chlamydial infections

Most Recent Events

  • 25 Nov 2004 Discontinued - Preclinical for Chlamydial infections in USA (unspecified route)
  • 25 Aug 2000 Antex has licensed the use of BioSante Pharmaceuticals' calcium phosphate nanoparticle technology as an adjuvant in its Chlamydophila pneumonia vaccine
  • 14 May 1999 Preclinical development for Chlamydial infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top